- 1 PDE5 inhibition and Alzheimer's disease risk: a mendelian randomisation study
- 2 **Authors:** Marta Alcalde-Herraiz¹, Benjamin Woolf^{2,3,4}, Junqing Xie¹, Emma Anderson⁵,
- 3 Dipender Gill⁶, Ioanna Tzoulaki^{6,7,8}, Laura M Winchester⁹, James Yarmolinsky⁶, Daniel
- 4 Prieto-Alhambra^{1,10}, Danielle Newby¹
- 6 ¹Centre for Statistics in Medicine and NIHR Biomedical Research Centre Oxford,
- 7 NDORMS, University of Oxford, Oxford, UK
- 8 ²School of Psychological Science, University of Bristol, Bristol, United Kingdom
- 9 ³MRC Integrative Epidemiology Unit, University of Bristol, Bristol, United Kingdom
- 10 ⁴MRC Biostatistics Unit, University of Cambridge, Cambridge, United Kingdom
- 11 ⁵Division of Psychiatry, University College of London, London, UK
- 12 ⁶Department of Epidemiology and Biostatistics, School of Public Health, Imperial
- 13 College London, London, UK
- ⁷MRC-PHE Centre for Environment, School of Public Health, Imperial College London,
- 15 London, UK

- 16 ⁸Department of Hygiene and Epidemiology, University of Ioannina Medical School,
- 17 Ioannina, Greece
- 18 ⁹Department of Psychiatry, Warneford Hospital, Oxford, UK
- 19 ¹⁰Department of Medical Informatics, Erasmus University Medical Centre, Rotterdam,
- 20 the Netherlands
- 21 Corresponding author:
- 22 Prof. Daniel Prieto-Alhambra
- 23 Botnar Research Centre, Windmill Road, OX37LD, Oxford, United Kingdom

- Email: daniel.prietoalhambra@ndorms.ox.ac.uk

Abstract

24

25

26

- **INTRODUCTION:** While preclinical studies suggest that Phosphodiesterase 5 (PDE5)
- 27 inhibition may reduce cognitive impairment, findings from observational studies on
- 28 whether PDE5 inhibitors reduce Alzheimer's disease (AD) risk have been inconsistent.
- 29 **METHODS:** A two-sample *cis-*Mendelian Randomisation (MR) analysis was conducted
- 30 to estimate the causal effect of PDE5 inhibition on AD risk. The analysis was performed
- 31 across four different genome-wide association studies (GWAS) of AD to enhance
- 32 evidence reliability through triangulation. Additionally, a sex-stratified MR analysis using
- data from UK Biobank was performed to assess potential sex-specific effects.
- 34 **RESULTS:** No evidence of a causal association between PDE5 inhibition and AD risk
- was found in the main analyses or sex-stratified analysis.
- 36 **DISCUSSION:** MR findings suggest that PDE5 inhibitors are unlikely to decrease the
- 37 risk of AD. Further research is needed to thoroughly understand the impact of PDE5
- 38 inhibitors on the risk of Alzheimer's disease.

39 Keywords

- 40 Alzheimer's disease, Mendelian randomisation, PDE-5, Phosphodiesterase-5,
- 41 dementia, sildenafil.

1. BACKGROUND

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia. It is characterised by the accumulation of beta-amyloid plagues and neurofibrillary tangles in the brain, leading to a gradual deterioration of cognitive function and memory¹. With the global increase in life expectancy, AD is rapidly emerging as a significant public health thread worldwide². Recently, the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK approved Lecanemab for treating adults in the early stages of AD³. While the treatment has been shown effective for slowing the disease progression, the National Institute for Health and Care Excellence (NICE) has not recommended its availability on the NHS. arising concerns about its cost-effectiveness⁴. There is therefore still a scarcity of drugs that can effectively treat or prevent AD. Several studies have identified numerous modifiable risk factors that may be associated with AD⁵, offering the potential opportunity for intervention through drug repurposing strategies⁶. This strategy aims to identify new therapeutic uses for existing drugs that have already been approved. In terms of cost-effectiveness, reduced drug-development time, and lower risk of failure, repurposing presents a highly advantageous strategy. Within this context, antihypertensive and related medications have been previously highlighted as promising candidates for AD prevention⁷. Specifically, Phosphodiesterase 5 (PDE5) inhibitors have gained growing interest due to their potential neuroprotective effects⁸.

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

PDE5 inhibitors (i.e., sildenafil, vardenafil, tadalafil, and avanafil) are mainly used for the treatment of erectile dysfunction (ED) and pulmonary arterial hypertension (PAH)^{9,10}. PDE5 is an enzyme present in smooth muscle cells whose inhibition has been shown to induce vascular smooth relaxation and vasodilatation. Simultaneously, this results in a reduction of diastolic blood pressure¹¹. Some preclinical models have also highlighted the potential of PDE5 inhibitors on improving memory function¹², although these results were not observed in subsequent clinical studies. Conflicting results have also been reported in observational studies 13,14, where confounding, time-related bias or reverse causation can play a key role. Alternatively, Mendelian randomisation (MR) can offer a robust approach to investigate causal relationships overcoming some of the limitations of observational research, as well as allowing for triangulation of evidence^{15,16}. Specifically, drug target MR is an analytical method that uses genetic variants within or near the gene encoding the risk factor (cisvariants) as instruments to proxy the exposure 15,17. Since alleles are randomly allocated during meiosis, this approach can minimise the risk of confounding that typically affects traditional observational studies, provided that all underlying MR assumptions are met. In this study, we performed a two-sample cis-MR analysis to estimate the causal effect of genetically proxied PDE5 inhibition and the risk of AD. To investigate this, we have used diastolic blood pressure as a surrogate biomarker. Furthermore, we also

conducted a stratified by sex MR analysis, where we used UK Biobank (UKB) to identify

88 AD cases.

2. METHODS

2.1. Study design

We performed a two-step *cis*-Mendelian Randomisation analysis to estimate the causal effect between genetically proxied PDE5 inhibition and AD risk. We scaled the effect of PDE5 inhibition based on a surrogate biomarker -diastolic blood pressure^{15,18}. We used four different genome-wide association study (GWAS) of AD, each one differing by the sample size, heritability value, and the use of by-proxy cases. Additionally, we performed a sex-stratified analysis using UKB dataset to identify AD cases. Figure 1 summarises the study design.

2.2. Data sources

2.2.1. Variant-risk factor estimates

Variant-exposure estimates were extracted from a GWAS of diastolic blood pressure ¹⁹. We used diastolic blood pressure (DBP) instead of systolic blood pressure (SBP) as PDE5 inhibition is known to have a greater impact on the former ¹¹. Evangelou *et al.* GWAS meta-analysed 77 cohorts (n = 757,601) participating in the International Consortium for Blood Pressure Genome (ICBP) ²⁰ and UKB ²¹. Blood pressure for each individual in the participating cohorts was measured in mmHg using either manual or automated readings. All participating cohorts adjusted for age, age ², sex, body mass index, and study-specific covariates. UKB cohort further corrected BP measures for those with self-reported medication use. Further information about study design,

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

participants, and genotype quality control of this GWAS can be found in the original publication GWAS estimates were measured in mmHg change per effect allele, and SNPs positions were reported in hg19/GRCh37 coordinates. 2.2.2. Variant-outcome estimates Genetic variant-outcome associations were derived from the AD GWAS published by Lambert et al.²² which conducted a two-stage meta-analysis of GWAS in individuals of European ancestry. We used estimates from stage 1, which consisted of 54,162 participants (17,008 AD cases and 37,154 controls) containing 7,055,881 genotyped and imputed variants. Further details of the databases included in this meta-analysis can be found in Supplement (Note 1 and Table 1). As secondary outcomes, we used three different AD GWAS: Rojas et al.²³ (N = 409,435), Bellenguez et al.²⁴ (N = 487,511) and Wightman et al.²⁵ (N = 398,108). All of them included only European participants. More details about the study populations can be found in the respective original publications and in supplementary (Note 1 and Table 1). We included these additional AD GWAS as secondary outcomes to validate our main study results. We did this due to the following reasons: (1) although they have bigger sample sizes, these AD GWAS have smaller SNP-based heritability value compared to Lambert AD GWAS: (2) the AD GWAS conducted by Rojas and Bellenguez contain a proportion of by-proxy-cases for AD; and, 3) Rojas and Bellenguez GWAS included

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

UKB, as well as Evangelou blood pressure GWAS, and we wanted to avoid sample overlap as can lead to biased results in the presence of weak instruments²⁶. All GWAS estimates were reported on the log(OR) scale. SNP coordinates were in hg19/GRCh37 assembly, except Rojas et al. GWAS, which was in the hg38/GRCh38 assembly. We aligned the coordinates of this GWAS from hg38/GRCh38 to hg19/GRCh37 using LiftOver²⁷. In the sex-specific analysis, we used UKB²¹ to estimate the variant-outcome effects. UKB is a large population-based cohort study of over 500,000 participants aged 40 to 69 at recruitment (2006 and 2010). UKB collected lifestyle data and biological samples for genotyping²⁸. Genotyping, performed by Affymetrix, includes 784,256 autosomal variants. Imputation was done using the Haplotype Reference Consortium and UK10K panels, covering 93 million SNPs. Health outcomes, including dementia and AD, were ascertained using validated algorithms combining baseline data and linked hospital and death records, with follow-up data until December 2022 (https://biobank.ndph.ox.ac.uk/showcase/refer.cgi?id=460). In total, there are around 10,000 of dementia cases recorded in UKB. 2.3. Statistical analysis 2.3.1. Instrument selection Instrumental variables used in MR must (1) be associated with the exposure, (2) not be associated with the outcome through confounding pathways, and (3) not affect the outcome except via the exposure²⁹. Instrumental variables to proxy PDE5 inhibition

were obtained from a previous study that also targeted PDE5 inhibition³⁰. This study selected five *cis*-genetic variants within the PDE5 gene (chromosome 4, position in GRCh37/hg19 120,415,550-120,550-146). These variants were associated with PDE5 gene expression in blood at genome-wide significance (P-Value<5·10⁻⁸) and clumped using the P-Values of their associations with diastolic blood pressure (r²<0.35, window = 10,000 kilobases). Instruments from this study were validated using two positive control outcomes (erectile dysfunction and pulmonary hypertension).

These five variants extracted from Woolf *et al.* study were used as instruments for this study (Table 1). The variant with strongest association (i.e., lowest P-Value) was rs66887589 (Beta = -0.16 respect allele T, 95%CI = -0.2 to -0.12). Variant rs17355550 was the one with weakest association with DBP (Beta = -0.14 respect allele C, 95%CI = -0.23 to -0.04).

2.3.2. Main analysis

Mendelian randomisation estimates were calculated using the inverse-variance weighted method accounting for correlation between variants³¹. We used the linkage disequilibrium matrix corresponding to European ancestry participants with the 1000 Genomes reference panel phase 3. Exposure alleles and outcome alleles were harmonised with respect to the linkage disequilibrium matrix. All MR estimates were reported as OR. We scaled our estimates to represent a daily 100mg dose of sildenafil, knowing that this amount decreases 5.5mmHg DBP.

2.3.3. Sex-stratified analysis

As AD is more prevalent in women compared to men³², we repeated the main analysis separately in females and males. We used the same variant-risk factor GWAS as in the main analysis (described in section Methods/Data sources/Variant-risk factor estimates), as previous research showed that SNP effects were identical for both, the mixed and the specific sex analysis³³. We used UKB to calculate genetic variants-AD associations separately for both females and males.

We used the algorithmically-defined dementia types to restrict our UK Biobank cohort to participants without other forms of dementia (frontotemporal, vascular, or all cause of

participants without other forms of dementia (frontotemporal, vascular, or all cause of dementia – including only those with AD-). AD cases were classified as those with an AD report, whereas AD controls were those without one. All UKB variable fields IDs used in the study can be found in Supplementary Table 2.

We estimated the effect size of the genetic instruments on the algorithmically defined AD (separately for each sex) using a logistic regression. We used age at first assessment, the genetic batch, and the first 10 genetic principal components as covariates in the model. Beta coefficients obtained from the two different regressions were used later for computing the MR estimates.

MR effects were reported as OR per 5.5mmHg decrease in DBP.

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

2.4. Sensitivity analysis 2.4.1. Two-Step *cis-*Mendelian randomization To account for any potential horizontal pleiotropic effects, we performed two-step *cis*-MR. This approach employs a two-step mediation strategy to account for potential pleiotropic pathways by adjusting variant-outcome associations³⁴. Hence, this approach is used to adjust our MR estimates for any effect mediated by other related traits. We adjusted our analysis for body mass index (BMI), as its inclusion as a covariate in the DBP GWAS can induce collider bias³⁵. 2.4.2. Leave-one-out analysis To assess whether the results from the main analysis were driven by a single instrument, we performed leave-one-out analysis³⁶. In this approach, one SNP from the instrumental set is removed and the estimate causal effect is re-calculated. We performed this analysis for each one of the AD GWAS included in this study. 2.5. Software and implementation We used R (version 3.2) for this study. The main packages used included TwoSampleMR³⁷, TwoStepCisMR³⁴, coloc³⁸, liftOver²⁷, dplyr³⁹, and ggplot2⁴⁰. This manuscript was written according to the STROBE-MR reporting guidelines⁴¹. analytical code public GitHub repository: can be found in the

https://github.com/oxford-pharmacoepi/PDE5_AD_MendelianRandomisation

3. RESULTS

219

220 3.1. Main analysis 221 We found little evidence of an association between genetically proxied PDE5 inhibition 222 and AD risk using Lambert's et al. GWAS (OR = 1.00, 95% confidence interval 0.96 to 223 1.04, P-Value = 0.96). These results were consistent when using the other AD GWAS 224 data (Figure 2). 225 226 Refer to Supplementary Table 3 to see the linkage disequilibrium matrix employed. 227 Harmonised variant-risk factor and variant-outcome effects can be found in 228 Supplementary Table 4. SNPs effect on the exposure against SNPs effects on the 229 outcome (Lambert's et al) can be found in Supplementary Figure 1. 230 3.2. Sex-stratified analysis 231 From the 502,230 participants in UKB, we excluded 6,153 participants because they 232 were diagnosed with vascular dementia, frontotemporal dementia or other forms of 233 dementia (Supplementary Figure 2). After further restricting to individuals with 234 genotyped data, we obtained a cohort of 262,037 females with 2,030 AD cases, and a 235 cohort of 220,352 males with 1,722 cases. Baseline characteristics of the respective 236 cohorts can be found in Supplementary Table 5. 237 238 MR results for both sex were consistent with the main analysis (Supplementary Figure 239 3), showing no association between genetically proxied PDE5 inhibition and AD risk 240 (Male: scaled OR = 1.04, 95%CI = 0.97 to 1.11, P-Value = 0.3; Female: scaled OR = 241 0.95, 95%CI = 0.88 to 1.03, P-Value = 0.2).

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

3.3. Sensitivity analyses 3.3.1. Two-Step *cis-*Mendelian randomization Results from the two-step *cis*-MR were consistent with the main findings (Supplementary Table 6), suggesting that BMI did not induce bias to our results. 3.3.2. Leave-one-out There was little evidence to suggest that any of the instruments was driven to the obtained results was found in the leave-one-out analysis. All results were consistent with the main findings (Supplementary Table 7). 4. DISCUSSION In this study, we used drug target MR to investigate the association between genetically proxied PDE5 inhibition and the risk of AD. Using DBP to scale PDE5 inhibition, our analysis showed little evidence of an effect of PDE5 inhibition on AD risk using a variety of AD GWAS datasets. Results stratifying by sex also showed no evidence of a causal association. PDE5 is an enzyme responsible for degrading cyclic guanosine monophosphate (cGMP)⁴², a molecule that actives protein kinase G (PKG). PKG plays a key role in the regulation of smooth muscle relaxation, particularly in blood vessels. In addition to its vascular effects, the cGMP/PKG signalling have also been shown to play a role in neuronal plasticity⁴³⁻⁴⁵. Animal models have shown the potential of sildenafil enhancing memory and cognitive function⁴⁶⁻⁴⁹ while having other neuroprotective effects, such as

improving synaptic plasticity⁵⁰, or reducing amyloid burden⁴⁶. However, clinical studies results' regarding sildenafil efficacy to enhance cognition have not been yet conclusive¹², although it has been recently shown to improve brain blood flow⁸.

Interestingly, observational studies have also found contradictory results. In 2021, Fang *et al.*¹³ developed an endophenotype network analysis where sildenafil was identified as a candidate drug in AD. They further conducted an observational study that suggested a reduction of 69% the risk of AD among sildenafil users compared to nonusers. This result was not aligned with a new-user active comparator cohort study conducted by Desai *et al.* (2022)¹⁴, where they did not find any evidence of an association between sildenafil and endothelin receptor antagonist users in people with PAH. Strengths, limitations and differences between the previous two observational studies have been extensively discussed elsewhere^{14,51,52}, mainly pointing to issues regarding the target population and the study design.

Our study presents genetic evidence that supports Desai *et al.*'s results. However, there are significant differences in the interpretation of both studies. First, Desai and colleagues included other dementias (vascular dementia, senile, pre-senile, or unspecified dementia) rather than AD to define the outcome, which can bias the results to the null if sildenafil has only impact on AD. In our study, we used different GWAS studies for AD, each one with different definition. For example, the main study outcome (Lambert's *et al.*²²) did include (although in small proportion) participants with mixed AD and vascular dementia (Supplementary Note 1) to define AD, as well as Bellenguez *et*

al.²⁴ definition. However, Wightman²⁵ and De Rojas²³ used a more specific definition for AD. Second, they restricted the study population to participants with PAH to minimise the risk of confounding by indication, reducing significantly the study population sample size. This can result in a lack of statistical power and generalisability to the general population, not only because of the sample size but also because, given the high mortality rate among medicated PAH patients, it can be that participants did not live long enough to develop AD. However, in our study we used Mendelian randomisation, which assumes that alleles are randomised at meiosis, we could study the impact of genetically proxied PDE5 inhibition, instrumented in a wider European population. Third, whereas they studied the impact of sildenafil usage on AD, our study did not assess that. Instead, we studied the effect of having lower levels of PDE5 in a lifelong time.

AD has been reported to be more prevalent in women³², whereas sildenafil is mainly prescribed to men. Hence, we performed a sex-stratified analysis using data from UKB to estimate the variant-outcome associations independently for males and females. Our findings indicated that genetically proxied PDE5 inhibition was not associated with a reduced risk of AD in either sex. However, both analyses were influenced by a significant case-control imbalance ratios, with only around 0.8% of participants being classified as cases. Hence, our sex-stratified analysis can be underpowered to detect any association.

A previous observational study conducted only in men diagnosed with ED had identified an association between the use of PDE5 inhibitors and decrease risk of AD⁵³. The

cohort study compared users of PDE5 inhibitors with non-users, based on the assumption that patients continued the treatment after the initial prescription. However, PDE5 inhibitors for ED are typically taken when required rather than regularly. This intermittent use challenges the assumption that participants consistently followed up with the treatment once prescribed, potentially impacting the study's conclusions.

Our study has several strengths that enhance the robustness of our findings. Firstly, we used MR to triangulate evidence from previous observational evidence, which is known to be less susceptible to unobserved confounding and reverse causation, compared to traditional observational studies^{15,17}. Second, we used instrumental variables that have been previously tested and validated using positive control outcomes, enhancing their reliability. Third, we included different AD definitions, each one prone to different bias, in the main analysis and obtained consistent evidence, ensuring the robustness of our results. Additionally, we further performed a two-step *cis*-MR to adjust for potential pleiotropic effect, where results were also consistent with the main analysis.

There are some limitations that must be considered when interpreting our results. First, by using MR, we are studying the effect of small lifelong effects of lower PDE5 levels on AD. However, PDE5 inhibitors are typically administered for a shorter time, in higher doses and at a specific point in time. Thus, the effect estimates from this study should not be interpreted as the effect of the pharmacological intervention, but as an approximation of the direction of the causal effects. Second, we only included European populations in our study (although in the sex-specific analysis we did not restrict to

increase the sample size, the proportion of non-white individuals was much smaller compared to white individuals). Therefore, our results are potentially not generalisable to other populations. Third, our model assumes that the effects of PDE5 inhibition are linear across the dose-response range. Forth, although we included different AD GWAS with different sources of bias, all of them relied on clinical diagnostic rather than postmortem autopsy (which is known to be the gold standard to detect the underlying cause of dementia). Hence, heterogeneity in our outcome might influence the results, as different types of dementia can have different risk factors⁵⁴.

Our study provides genetic evidence that PDE5 inhibitors are unlikely to decrease the risk of AD. Findings from this study have significant implications for our understanding of AD pathophysiology and the identification of PDE5 inhibitors potential therapeutic targets.

5. Data availability

All GWAS used are publicly available (see references to original publications and Supplementary Table 1). UK Biobank individual-level source data can be accessed by applying for access at http://ukbiobank.ac.uk/register-apply/. This research has been conducted using the UK Biobank Resource under Application Number 98358.

6. Acknowledgements

The authors express sincere gratitude to all individuals who generously participated in each one of the GWAS we have included in this study, as well as UK Biobank

participants. This work uses data provided by patients and collected by the NHS as part of their care and support.

7. Conflicts of interest

DG is the Chief Executive Officer of Sequoia Genetics, a private limited company that works with investors, pharma, biotech, and academia by performing research that leverages genetic data to help inform drug discovery and development. DG has financial interests in several biotechnology companies. DPA receives funding from the UK National Institute for Health and Care Research (NIHR) in the form of a senior research fellowship. DPA's group received partial support from the Oxford NIHR Biomedical Research Centre. DPA's department has received grant/s from Amgen, Chiesi-Taylor, Lilly, Janssen, Novartis, and UCB Biopharma. His research group has received consultancy fees from AstraZeneca and UCB Biopharma. Amgen, Astellas, Janssen, Synapse Management Partners, and UCB Biopharma have funded or supported training programmes organised by DPA's department. All other authors report no conflicts of interest.


Table 1: Single nucleotide polymorphisms employed as instruments for the Mendelian randomisation analysis.


Note: SNP = Single nucleotide polymorphism, SE = Standard error, EAF = effect allele frequency.

				Diastol	ic blood _l	eQTL (N = 31,684)			
SNP	Effect allele	Other allele	EAF	Beta (mm Hg)	SE	P- Value	Sample size	F- statis tic	P-Value
rs66887589	С	Т	0.48	0.16	0.02	2e-20	754,581	86	1.9e-40
rs10050092	С	Т	0.34	-0.13	0.02	9e-13	754,583	51	1.5e-18
rs12646525	Т	С	0.22	-0.10	0.02	7e-06	746,319	20	1.5e-9
rs80223330	Α	G	0.14	0.10	0.03	0.0001	749,960	15	2.1e-34
rs17355550	С	Т	0.03	-0.14	0.05	0.004	746,320	8	3.5e-8

373

374








Fig. 1: Scheme of the study design. GWAS = Genome wide association study.

377

378

Outcome study	Sample size	Cases (%)		OR (95% CI)	P-Value
Main analysis					
Lambert et al. (2013)	54,162	17,008 (31)		1 (0.96, 1.04)	0.96
Secondary analyses					
Wightman et al. (2021)	398,108	39,968 (10)	-	1.02 (1, 1.04)	0.11
De Rojas et al. (2021)	409,435	81,611 (20)		1 (0.98, 1.02)	0.76
Bellenguez et al. (2022)	487,511	85,934 (18)		1 (0.98, 1.01)	0.77
			0.90 1.0 1.1 Odds Ratio		

Fig. 2: Results from the Mendelian randomization. Odds ratio is scaled to represent 100mg dose of sildenafil (which reduces 5mmHg diastolic blood pressure). Note: OR = Odds ratio, CI = Confidence interval.

References

- 387 1. NHS. Alzheimer's disease. 2024; https://www.nhs.uk/conditions/alzheimers-disease/, 2024; https://www.nhs.uk/conditions/alzheimers-disease/, 2024.
- 389 2. Alzheimer's A. 2016 Alzheimer's disease facts and figures. *Alzheimers Dement.* 390 2016;12(4):459-509.
- 391 3. GOV.UK. Lecanemab licensed for adult patients in the early stages of Alzheimer's disease. 2024; <a href="https://www.gov.uk/government/news/lecanemab-licensed-for-adult-patients-in-the-early-stages-of-alzheimers-disease#:~:text=Lecanemab%20is%20a%20monoclonal%20antibody,the%20progression%20of%20the%20disease, 2024.
- NICE. Benefits of new Alzheimer's treatment lecanemab are too small to justify the cost to the NHS. 2024; https://www.nice.org.uk/news/articles/benefits-of-new-alzheimer-s-treatment-lecanemab-are-too-small-to-justify-the-cost-to-the-nhs, 399
- 400 5. Livingston G, Huntley J, Liu KY, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. *Lancet*. 402 2024;404(10452):572-628.
- 403 6. Pushpakom S, Iorio F, Eyers PA, et al. Drug repurposing: progress, challenges and recommendations. *Nat Rev Drug Discov.* 2019;18(1):41-58.
- 405 7. Hughes D, Judge C, Murphy R, et al. Association of Blood Pressure Lowering With Incident Dementia or Cognitive Impairment: A Systematic Review and Meta-analysis. *JAMA*. 2020;323(19):1934-1944.
- Webb AJS, Birks JS, Feakins KA, et al. Cerebrovascular Effects of Sildenafil in Small Vessel Disease: The OxHARP Trial. *Circ Res.* 2024;135(2):320-331.
- 9. Barnett CF, Machado RF. Sildenafil in the treatment of pulmonary hypertension.
 Vasc Health Risk Manag. 2006;2(4):411-422.
- 412 10. Levine SB. Pharmacologic treatment of erectile dysfunction. *BMJ*. 413 2004;329(7459):E310-311.
- 414 11. Kloner RA. Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction. *Circulation*. 416 2004;110(19):3149-3155.
- 417 12. Zuccarello E, Acquarone E, Calcagno E, et al. Development of novel phosphodiesterase 5 inhibitors for the therapy of Alzheimer's disease. *Biochem Pharmacol.* 2020;176:113818.
- 420 13. Fang J, Zhang P, Zhou Y, et al. Endophenotype-based in silico network medicine 421 discovery combined with insurance record data mining identifies sildenafil as a 422 candidate drug for Alzheimer's disease. *Nat Aging*. 2021;1(12):1175-1188.
- 423 14. Desai RJ, Mahesri M, Lee SB, et al. No association between initiation of phosphodiesterase-5 inhibitors and risk of incident Alzheimer's disease and related dementia: results from the Drug Repurposing for Effective Alzheimer's Medicines study. *Brain Commun.* 2022;4(5):fcac247.
- 427 15. Schmidt AF, Finan C, Gordillo-Maranon M, et al. Genetic drug target validation using Mendelian randomisation. *Nat Commun.* 2020;11(1):3255.

- 429 16. Smith GD, Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? *Int J Epidemiol.* 2003;32(1):1-22.
- 432 17. Gill D, Georgakis MK, Walker VM, et al. Mendelian randomization for studying the effects of perturbing drug targets. *Wellcome Open Res.* 2021;6:16.
- 434 18. Schmidt AF, Hingorani AD, Finan C. Human Genomics and Drug Development. 435 Cold Spring Harb Perspect Med. 2022;12(2).
- 436 19. Evangelou E, Warren HR, Mosen-Ansorena D, et al. Publisher Correction: 437 Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits. *Nat Genet*. 2018;50(12):1755.
- Wain LV, Vaez A, Jansen R, et al. Novel Blood Pressure Locus and Gene Discovery Using Genome-Wide Association Study and Expression Data Sets From Blood and the Kidney. *Hypertension*. 2017;70(3):e4-e19.
- Sudlow C, Gallacher J, Allen N, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS Med.* 2015;12(3):e1001779.
- Lambert JC, Ibrahim-Verbaas CA, Harold D, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. *Nat Genet*. 2013;45(12):1452-1458.
- de Rojas I, Moreno-Grau S, Tesi N, et al. Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. *Nat Commun.* 2021;12(1):3417.
- 451 24. Bellenguez C, Kucukali F, Jansen IE, et al. New insights into the genetic etiology of Alzheimer's disease and related dementias. *Nat Genet.* 2022;54(4):412-436.
- Wightman DP, Jansen IE, Savage JE, et al. Author Correction: A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer's disease. *Nat Genet*. 2021;53(12):1722.
- 456 26. Sadreev II, Elsworth BL, Mitchell RE, et al. Navigating sample overlap, winner's curse and weak instrument bias in Mendelian randomization studies using the UK Biobank. *medRxiv.* 2021:2021.2006.2028.21259622.
- 459 27. Hinrichs AS, Karolchik D, Baertsch R, et al. The UCSC Genome Browser 460 Database: update 2006. *Nucleic Acids Res.* 2006;34(Database issue):D590-598.
- 461 28. Bycroft C, Freeman C, Petkova D, et al. The UK Biobank resource with deep phenotyping and genomic data. *Nature*. 2018;562(7726):203-209.
- 463 29. Burgess S, Davey Smith G, Davies NM, et al. Guidelines for performing Mendelian randomization investigations: update for summer 2023. *Wellcome Open Res.* 2019;4:186.
- Woolf B, Rajasundaram S, Cronje HT, Yarmolinsky J, Burgess S, Gill D. A drug target for erectile dysfunction to help improve fertility, sexual activity, and wellbeing: mendelian randomisation study. *BMJ*. 2023;383:e076197.
- 469 31. Burgess S, Zuber V, Valdes-Marquez E, Sun BB, Hopewell JC. Mendelian randomization with fine-mapped genetic data: Choosing from large numbers of correlated instrumental variables. *Genet Epidemiol.* 2017;41(8):714-725.
- 472 32. Andersen K, Launer LJ, Dewey ME, et al. Gender differences in the incidence of AD and vascular dementia: The EURODEM Studies. EURODEM Incidence Research Group. *Neurology*. 1999;53(9):1992-1997.

- Woolf B, Mason A, Zagkos L, Sallis H, Munafo MR, Gill D. MRSamePopTest: introducing a simple falsification test for the two-sample mendelian randomisation 'same population' assumption. *BMC Res Notes*. 2024;17(1):27.
- 478 34. Woolf B, Zagkos L, Gill D. TwoStepCisMR: A Novel Method and R Package for Attenuating Bias in cis-Mendelian Randomization Analyses. *Genes (Basel)*. 480 2022;13(9).
- Hartwig FP, Tilling K, Davey Smith G, Lawlor DA, Borges MC. Bias in two-sample Mendelian randomization when using heritable covariable-adjusted summary associations. *Int J Epidemiol.* 2021;50(5):1639-1650.
- 484 36. Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. *BMJ*. 2018;362:k601.
- Hemani G, Zheng J, Elsworth B, et al. The MR-Base platform supports systematic causal inference across the human phenome. *Elife*. 2018;7.
- 488 38. Giambartolomei C, Vukcevic D, Schadt EE, et al. Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. *PLoS Genet*. 2014;10(5):e1004383.
- 491 39. *dplyr: A Grammar of Data Manipulation* [computer program]. Version R package version 1.1.4, https://github.com/tidyverse/dplyr2023.
- 493 40. ggplot2: Elegant Graphics for Data Analysis [computer program]. 2016.
- 494 41. Skrivankova VW, Richmond RC, Woolf BAR, et al. Strengthening the reporting of observational studies in epidemiology using mendelian randomisation (STROBE-496 MR): explanation and elaboration. *BMJ*. 2021;375:n2233.
- 497 42. Tropea MR, Gulisano W, Vacanti V, Arancio O, Puzzo D, Palmeri A. Nitric oxide/cGMP/CREB pathway and amyloid-beta crosstalk: From physiology to Alzheimer's disease. *Free Radic Biol Med.* 2022;193(Pt 2):657-668.
- 500 43. Bollen E, Puzzo D, Rutten K, et al. Improved long-term memory via enhancing cGMP-PKG signaling requires cAMP-PKA signaling. *Neuropsychopharmacology*. 2014;39(11):2497-2505.
- 503 44. Ota KT, Pierre VJ, Ploski JE, Queen K, Schafe GE. The NO-cGMP-PKG signaling pathway regulates synaptic plasticity and fear memory consolidation in the lateral amygdala via activation of ERK/MAP kinase. *Learn Mem.* 2008;15(10):792-805.
- 507 45. Prickaerts J, Sik A, van Staveren WC, et al. Phosphodiesterase type 5 inhibition improves early memory consolidation of object information. *Neurochem Int.* 2004;45(6):915-928.
- 510 46. Puzzo D, Staniszewski A, Deng SX, et al. Phosphodiesterase 5 inhibition improves synaptic function, memory, and amyloid-beta load in an Alzheimer's disease mouse model. *J Neurosci.* 2009;29(25):8075-8086.
- 513 47. Cuadrado-Tejedor M, Hervias I, Ricobaraza A, et al. Sildenafil restores cognitive function without affecting beta-amyloid burden in a mouse model of Alzheimer's disease. *Br J Pharmacol.* 2011;164(8):2029-2041.
- Hosseini-Sharifabad A, Ghahremani MH, Sabzevari O, et al. Effects of protein kinase A and G inhibitors on hippocampal cholinergic markers expressions in rolipram- and sildenafil-induced spatial memory improvement. *Pharmacol Biochem Behav.* 2012;101(3):311-319.

- 520 49. Prickaerts J, van Staveren WC, Sik A, et al. Effects of two selective phosphodiesterase type 5 inhibitors, sildenafil and vardenafil, on object recognition memory and hippocampal cyclic GMP levels in the rat. *Neuroscience*. 2002;113(2):351-361.
- 524 50. Palmeri A, Privitera L, Giunta S, Loreto C, Puzzo D. Inhibition of phosphodiesterase-5 rescues age-related impairment of synaptic plasticity and memory. *Behav Brain Res.* 2013;240:11-20.
- 527 51. Newby D. Are phosphodiesterase Type 5 inhibitors potential therapies for Alzheimer's disease and related dementias? *Brain Commun.* 2022;4(5):fcac260.
- 529 52. Her QL, Kahrs JC, Sturmer T. Comparator choices in pharmacoepidemiology studies of Alzheimer's disease. *Nat Aging.* 2023;3(7):791-792.
- 53. Adesuyan M, Jani YH, Alsugeir D, et al. Phosphodiesterase Type 5 Inhibitors in Men With Erectile Dysfunction and the Risk of Alzheimer Disease: A Cohort Study. *Neurology*. 2024;102(4):e209131.
- 534 54. Anderson EL, Davies NM, Korologou-Linden R, Kivimaki M. Dementia 535 prevention: the Mendelian randomisation perspective. *J Neurol Neurosurg* 536 *Psychiatry.* 2024;95(4):384-390.